We read with great interest the paper by Markmann et al.entitled“Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant:The OCS Liver PROTECT randomized clinical trial”(1).In t...We read with great interest the paper by Markmann et al.entitled“Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant:The OCS Liver PROTECT randomized clinical trial”(1).In this multicenter randomized clinical trial,the authors compared posttransplant outcomes for recipients who received donation after brainstem death(DBD)or donation after circulatory death(DCD)livers preserved using ischemic cold storage(ICS)or a portable normothermic machine perfusion(NMP)[Organ Care System(OCS)Liver].The primary endpoint was the incidence of early allograft dysfunction(EAD)as defined by Olthoff et al.criteria(2).The trial was methodologically designed to test both non-inferiority on the primary endpoint,and superiority if non-inferiority was achieved.This study was conducted from 2016 to 2019 at 20 US liver transplant programs.展开更多
文摘We read with great interest the paper by Markmann et al.entitled“Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant:The OCS Liver PROTECT randomized clinical trial”(1).In this multicenter randomized clinical trial,the authors compared posttransplant outcomes for recipients who received donation after brainstem death(DBD)or donation after circulatory death(DCD)livers preserved using ischemic cold storage(ICS)or a portable normothermic machine perfusion(NMP)[Organ Care System(OCS)Liver].The primary endpoint was the incidence of early allograft dysfunction(EAD)as defined by Olthoff et al.criteria(2).The trial was methodologically designed to test both non-inferiority on the primary endpoint,and superiority if non-inferiority was achieved.This study was conducted from 2016 to 2019 at 20 US liver transplant programs.
